ROCHE HOLDING LTD S/ADR (RHHBY) SEC filings
RHHBY SEC filings — 10-K, 10-Q, 8-K and the rest — each read against the price at its own news timestamp. Back to the RHHBY overview →
3 measured RHHBY SEC filing events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus | Press release | -0.65% | -2.02% | |
| New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus | Press release | -0.02% | +1.82% | |
| Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk | Press release | -0.03% | -1.00% |
Keep exploring
More RHHBY: earnings → · analyst actions → · RHHBY overview →
Other Healthcare names and their SEC filings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Glaukos Corporation (GKOS) | 452 | +0.04% | 51% |
| Cosmos Health Inc. (COSM) | 450 | 0.00% | 50% |
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Arvinas, Inc. (ARVN) | 442 | -0.26% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its SEC filings — that is what the link opens.